Results from a clinical trial of its drug in the 'fatty liver' disease NASH sent $AKRO's stock soaring
Encouraging data on a South San Francisco company's drug targeting the fatty liver disease NASH pushed its stock 120% higher in early trading Tuesday.
Most side effects — diarrhea, nausea, increased appetite and frequent bowel movements — were transient, the company said. EFX, formerly known as AKR-001, is Akero's lead product candidate, designed not only to reduce liver fat and inflammation but to reduce fibrosis. It is injected once a week into a layer of skin.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Officer Injured by Theft Suspects Fleeing Scene in San FranciscoA police officer investigating a catalytic converter theft early Monday was injured after being hit by the suspects’ car in San Francisco’s Russian Hill neighborhood, police said.
Read more »
Fleeing catalytic converter theft suspects injure police officer in San Francisco; 1 arrestedA police officer investigating a catalytic converter theft early Monday was injured after being hit by the suspects' car in San Francisco's Russian Hill neighborhood, police said.
Read more »
Forget 2011, Kyle Busch Close to Deal with Richard Childress Racing NASCAR Cup TeamTwo-time NASCAR Cup champion and RCR could confirm the deal as early as Tuesday.
Read more »
Warriors, 49ers and Giants land on Forbes' 2022 most valuable teams list - San Francisco Business TimesThe NFL has made a run for the top spots this year, bumping the MLB and the NBA out of the top three.
Read more »
Universal Paragon Corp. proposes Project Axon at Sierra Point in Brisbane - San Francisco Business TimesThe proposed hotel near the Brisbane Marina is envisioned with over 600 rooms and an outdoor wedding chapel. An adjacent life sciences building will rise 11 stories.
Read more »